Harmony Biosciences Holdings, Inc. - HRMY Total Company Value-to-Revenue Ratio

Public company logo of harmonybiosciences.com (HRMY)

Harmony Biosciences revenues rely on insurance reimbursements for the treatment of rare nervous system disorders. The Enterprise Value to Sales ratio on GURU.Markets reflects the current scaling potential, where the value 1413.83 serves as the baseline indicator. The business's non-cyclical resilience is ensured by the demand for therapy, while absolute pricing power is secured by the unique drug Wakix for the treatment of sleepiness.

Harmony Biosciences (HRMY): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Harmony Corp - analytical breakdowns and key metrics (HRMY)

- money and cash flow information:
Fundamental company valuation:HRMY, harmonybiosciences.com
Manufactured product of Harmony Pharma

The market values Harmony Biosciences (HRMY) through the lens of its ability to monetize unique developments. This indicator compares the total enterprise value with annual revenue, excluding the impact of debt load. By analyzing the EV/Sales valuation multiple, an investor determines the price of one dollar of revenue. For Harmony Biosciences (HRMY), a high valuation is justified by patent protection and the exclusive status of orphan drugs. This confirms the resilience of the business model in the face of regulatory barriers.

Competitor analysis

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|BHVN: Enterprise Value-to-Revenue Ratio|AMLX: EV/Sales Multiple|TRVI: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio Praxis Medicines|Enterprise Value-to-Revenue Multiple Anavex AVXL|Enterprise Value-to-Revenue Ratio CeriBell Corp (CBLL)|Enterprise Value-to-Revenue Coefficient PRTA|EV/Sales Multiple ALEC (Alector)|Annexon (ANNX) - Enterprise Value-to-Revenue Multiple|OMER - Enterprise Value-to-Revenue Ratio|NGNE (Neurogene) - Company Value to Revenue Ratio|ACIU: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE